Seco-Duocarmycin MA acts as a powerful ADC payload that covalently binds DNA, inducing apoptosis in malignant cells. As an ADC cytotoxin, it improves targeted drug delivery in antibody-drug conjugates, supporting innovative cancer treatment strategies.
Structure of 1613286-57-9
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
-- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-00811 | Duocarmycin DM free base | 1116745-06-2 | |
BADC-00337 | Seco-Duocarmycin TM | 1142188-60-0 | |
BADC-00223 | Duocarmycin A | 118292-34-5 | |
BADC-00362 | Duocarmycin B1 | 124325-93-5 | |
BADC-00341 | Seco-Duocarmycin SA | 152785-82-5 | |
BADC-00605 | Duocarmycin TM | 157922-77-5 | |
BADC-00332 | Seco-DuocarmycinCN | 1613286-54-6 | |
BADC-00333 | Seco-DuocarmycinDMG | 1613286-55-7 | |
BADC-00609 | Duocarmycin MB | 1613286-58-0 | |
BADC-00336 | Seco-Duocamycin GA | 1613286-59-1 |
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.